FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285083553> ?p ?o ?g. }

• W4285083553 abstract "Objective Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduce glycaemia and weight and improve insulin resistance (IR) via different mechanisms. We aim to evaluate and compare the ability of GLP-1 RAs and SGLT-2 inhibitors to ameliorate the IR of nonalcoholic fatty liver disease (NAFLD) patients. Data Synthesis Three electronic databases (Medline, Embase, PubMed) were searched from inception until March 2021. We selected randomized controlled trials comparing GLP-1 RAs and SGLT-2 inhibitors with control in adult NAFLD patients with or without T2DM. Network meta-analyses were performed using fixed and random effect models, and the mean difference (MD) with corresponding 95% confidence intervals (CI) were determined. The within-study risk of bias was assessed with the Cochrane collaborative risk assessment tool RoB. Results 25 studies with 1595 patients were included in this network meta-analysis. Among them, there were 448 patients, in 6 studies, who were not comorbid with T2DM. Following a mean treatment duration of 28.86 weeks, compared with the control group, GLP-1 RAs decreased the HOMA-IR (MD [95%CI]; -1.573[-2.523 to -0.495]), visceral fat (-0.637[-0.992 to -0.284]), weight (-2.394[-4.625 to -0.164]), fasting blood sugar (-0.662[-1.377 to -0.021]) and triglyceride (- 0.610[-1.056 to -0.188]). On the basis of existing studies, SGLT-2 inhibitors showed no statistically significant improvement in the above indicators. Compared with SGLT-2 inhibitors, GLP-1 RAs decreased visceral fat (-0.560[-0.961 to -0.131]) and triglyceride (-0.607[-1.095 to -0.117]) significantly. Conclusions GLP-1 RAs effectively improve IR in NAFLD, whereas SGLT-2 inhibitors show no apparent effect. Systematic Review Registration PROSPERO https://www.crd.york.ac.uk/PROSPERO/ , CRD42021251704" @default.
• W4285083553 created "2022-07-14" @default.
• W4285083553 creator A5007982436 @default.
• W4285083553 creator A5028317884 @default.
• W4285083553 creator A5054696776 @default.
• W4285083553 creator A5059406170 @default.
• W4285083553 creator A5060667885 @default.
• W4285083553 creator A5084222587 @default.
• W4285083553 date "2022-07-13" @default.
• W4285083553 modified "2023-10-15" @default.
• W4285083553 title "GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis" @default.
• W4285083553 cites W2010699829 @default.
• W4285083553 cites W2041501810 @default.
• W4285083553 cites W2042896975 @default.
• W4285083553 cites W2045280884 @default.
• W4285083553 cites W2053073979 @default.
• W4285083553 cites W2065285024 @default.
• W4285083553 cites W2075514437 @default.
• W4285083553 cites W2078374645 @default.
• W4285083553 cites W2084948079 @default.
• W4285083553 cites W2098923148 @default.
• W4285083553 cites W2102009612 @default.
• W4285083553 cites W2103052169 @default.
• W4285083553 cites W2109327370 @default.
• W4285083553 cites W2124038922 @default.
• W4285083553 cites W2125769789 @default.
• W4285083553 cites W2150959326 @default.
• W4285083553 cites W2157405334 @default.
• W4285083553 cites W2158849361 @default.
• W4285083553 cites W2166613497 @default.
• W4285083553 cites W2169274492 @default.
• W4285083553 cites W2204688218 @default.
• W4285083553 cites W2217349032 @default.
• W4285083553 cites W2512394360 @default.
• W4285083553 cites W2554228598 @default.
• W4285083553 cites W2588681363 @default.
• W4285083553 cites W2593976508 @default.
• W4285083553 cites W2615085659 @default.
• W4285083553 cites W2623056842 @default.
• W4285083553 cites W2626083631 @default.
• W4285083553 cites W2730596924 @default.
• W4285083553 cites W2734724639 @default.
• W4285083553 cites W2737083386 @default.
• W4285083553 cites W2784171922 @default.
• W4285083553 cites W2792768188 @default.
• W4285083553 cites W2808615577 @default.
• W4285083553 cites W2810423511 @default.
• W4285083553 cites W2890539106 @default.
• W4285083553 cites W2896061464 @default.
• W4285083553 cites W2905282109 @default.
• W4285083553 cites W2910652600 @default.
• W4285083553 cites W2913071400 @default.
• W4285083553 cites W2916700999 @default.
• W4285083553 cites W2974008202 @default.
• W4285083553 cites W3004644667 @default.
• W4285083553 cites W3007693094 @default.
• W4285083553 cites W3015579983 @default.
• W4285083553 cites W3019568499 @default.
• W4285083553 cites W3088344065 @default.
• W4285083553 cites W3092443860 @default.
• W4285083553 cites W3113858149 @default.
• W4285083553 cites W3115388830 @default.
• W4285083553 cites W3125674226 @default.
• W4285083553 cites W3130225195 @default.
• W4285083553 cites W3138370909 @default.
• W4285083553 cites W3155254720 @default.
• W4285083553 cites W3201690119 @default.
• W4285083553 cites W4233179469 @default.
• W4285083553 cites W4246340431 @default.
• W4285083553 doi "https://doi.org/10.3389/fendo.2022.923606" @default.
• W4285083553 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35909522" @default.
• W4285083553 hasPublicationYear "2022" @default.
• W4285083553 type Work @default.
• W4285083553 citedByCount "8" @default.
• W4285083553 countsByYear W42850835532022 @default.
• W4285083553 countsByYear W42850835532023 @default.
• W4285083553 crossrefType "journal-article" @default.
• W4285083553 hasAuthorship W4285083553A5007982436 @default.
• W4285083553 hasAuthorship W4285083553A5028317884 @default.
• W4285083553 hasAuthorship W4285083553A5054696776 @default.
• W4285083553 hasAuthorship W4285083553A5059406170 @default.
• W4285083553 hasAuthorship W4285083553A5060667885 @default.
• W4285083553 hasAuthorship W4285083553A5084222587 @default.
• W4285083553 hasBestOaLocation W42850835531 @default.
• W4285083553 hasConcept C126322002 @default.
• W4285083553 hasConcept C134018914 @default.
• W4285083553 hasConcept C168563851 @default.
• W4285083553 hasConcept C2776954865 @default.
• W4285083553 hasConcept C2777180221 @default.
• W4285083553 hasConcept C2777391703 @default.
• W4285083553 hasConcept C2778163477 @default.
• W4285083553 hasConcept C2778772119 @default.
• W4285083553 hasConcept C2778913445 @default.
• W4285083553 hasConcept C2779134260 @default.
• W4285083553 hasConcept C2779306644 @default.
• W4285083553 hasConcept C555293320 @default.
• W4285083553 hasConcept C71924100 @default.
• W4285083553 hasConcept C90924648 @default.
• W4285083553 hasConcept C95190672 @default.
• W4285083553 hasConceptScore W4285083553C126322002 @default.

• next